Clinical trials: Carfilzomib
Multiple Myeloma
Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib
The purpose of this Phase II study is to evaluate the safety and effectiveness (good and bad effects) of carfilzomib given as a 30-minute infusion and at a dose of 70 mg/m2 to treat patients with multiple myeloma (MM), who are…
- Trial name
- NCT02294357
- Testing
- Carfilzomib, Dexamethasone, Prednisone
- Where
- 7 sites in United States
- Volunteers
- 45 people
- Sponsor
- Oncotherapeutics
Cancer
A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2)
This open-label, 2-part Phase I/ randomized Phase II multi-center study is conducted to evaluate the safety, tolerability, pharmacokinetics (PK), and clinical activity of afuresertib in combination with carfilzomib versus…
- Trial name
- NCT02235740
- Testing
- Afuresertib, Carfilzomib
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Novartis
Relapsed Multiple Myeloma, End-stage Renal Disease
Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal Disease
The purpose of this study is to see how the body and the cancer react to carfilzomib, including measuring the amount of the study drug in the blood at certain times following dosing.
- Trial name
- NCT01949532
- Testing
- Carfilzomib
- Where
- 13 sites in United States, Australia and 1 more
- Volunteers
- 26 people
- Sponsor
- Amgen
Plasma Cell Myeloma
Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients
The purpose of this study it to compare the efficacity of isatuximab when combined to carfilzomib and dexamethasone versus carfilzomib and dexamethasone in patients with multiple myeloma already treated with 1 to 3 prior lines of…
- Trial name
- IKEMA (NCT03275285)
- Testing
- isatuximab SAR650984, carfilzomib, dexamethasone
- Where
- 70 sites in United States, Australia and 14 more
- Volunteers
- 302 people
- Sponsor
- Sanofi
Relapsed or Refractory Multiple Myeloma
Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet
A Study Evaluating Treatment of Multiple Myeloma with Carfilzomib in Combination with Pomalidomide and Dexamethasone
- Trial name
- SELECT (NCT04191616)
- Testing
- Carfilzomib, Dexamethasone, Pomalidomide
- Where
- 46 sites in United States, Denmark and 6 more
- Volunteers
- 54 people
- Sponsor
- Amgen
Multiple Myeloma
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
This study is for adults with multiple myeloma (a type of blood cancer) that has come back after being treated earlier or isn't responding to the current treatment.
- Trial name
- NCT07227311
- Testing
- Belantamab mafodotin, Dexamethasone, Pomalidomide
- Where
- 59 sites in United States, France and 6 more
- Volunteers
- 200 people
- Sponsor
- GlaxoSmithKline
Multiple Myeloma
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)
A Phase 2, open-label, dose escalation study to evaluate the safety and efficacy of venetoclax in combination with carfilzomib-dexamethasone (Kd) in participants with relapsed or refractory MM and have received 1 to 3 prior lines…
- Trial name
- NCT02899052
- Testing
- Carfilzomib, Venetoclax, Dexamethasone
- Where
- 32 sites in United States, Australia and 3 more
- Volunteers
- 120 people
- Sponsor
- AbbVie
Multiple Myeloma
Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma
The primary objective was to compare the progression-free survival of transplant ineligible patients newly diagnosed with multiple myeloma who were treated with carfilzomib, melphalan and prednisone (CMP) or with Velcade®…
- Trial name
- CLARION (NCT01818752)
- Testing
- Carfilzomib, Bortezomib, Melphalan
- Where
- 213 sites in United States, Argentina and 28 more
- Volunteers
- 955 people
- Sponsor
- Amgen
Multiple Myeloma
Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab
The purpose of this study is to compare the efficacy (rate of very good partial response [VGPR] or better as best response as defined by the International Myeloma Working Group [IMWG] criteria) of daratumumab subcutaneous…
- Trial name
- NCT03871829
- Testing
- Carfilzomib 20 mg/m^2, Carfilzomib 70 mg/m^2, Dexamethasone 40 mg
- Where
- 108 sites in United States, Belgium and 11 more
- Volunteers
- 88 people
- Sponsor
- Janssen Research & Development, LLC
Relapsed or Refractory Multiple Myeloma
A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers
The primary objective was to describe the safety profile of carfilzomib plus dexamethasone regimen in adults with relapsed or refractory multiple myeloma (RRMM) with 1 to 3 prior lines of therapy at study entry.
- Trial name
- NCT03512353
- Testing
- Dexamethasone, Carfilzomib
- Where
- 31 sites in United States
- Volunteers
- 7 people
- Sponsor
- Amgen
Relapsed Multiple Myeloma
Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma
The primary objective was to compare progression-free survival in adults with relapsed multiple myeloma who are receiving CRd vs participants receiving Rd in a randomized multicenter setting.
- Trial name
- NCT01080391
- Testing
- Dexamethasone, Lenalidomide, Carfilzomib
- Where
- 127 sites in United States, Austria and 18 more
- Volunteers
- 792 people
- Sponsor
- Amgen
Multiple Myeloma in Relapse
Non-interventional Study of Kyprolis® in Combination With Revlimid® and Dexamethasone or Dexamethasone Alone or in Combination With Darzalex® and Dexamethasone in Multiple Myeloma Patients
The objective of this non-interventional study (NIS) is to evaluate patients' adherence and persistence to carfilzomib therapy in combination with lenalidomide and dexamethasone or in combination with dexamethasone alone or in…
- Trial name
- CARO (NCT02970747)
- Testing
- Carfilzomib
- Where
- Germany
- Volunteers
- 359 people
- Sponsor
- iOMEDICO AG
Multiple Myeloma
Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients
The goal of this clinical research study is to evaluate the safety and effectiveness (good and bad effects) of ixazomib given as part of a combination therapy to treat subjects with relapsed (subjects whose disease came back) or…
- Trial name
- NCT02206425
- Testing
- Melphalan, Prednisone, Cyclophosphamide
- Where
- 12 sites in United States
- Volunteers
- 45 people
- Sponsor
- Oncotherapeutics
Relapsed or Refractory Multiple Myeloma
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
The purpose of the study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexamethasone (Kd) in the treatment of RRMM: SUCCESSOR-2.
- Trial name
- SUCCESSOR-2 (NCT05552976)
- Testing
- Mezigdomide, Carfilzomib, Dexamethasone
- Where
- 204 sites in United States, Argentina and 25 more
- Volunteers
- 606 people
- Sponsor
- Bristol-Myers Squibb
Multiple Myeloma
A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma
The purpose of this study is to evaluate the safety, tolerability, and dose regimen of daratumumab when administered in combination with various treatment regimens for the treatment of multiple myeloma.
- Trial name
- NCT01998971
- Testing
- Daratumumab, Velcade, Pomalidomide
- Where
- 22 sites in United States, France and 1 more
- Volunteers
- 240 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma
A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects
The primary objective was to determine the maximum tolerated dose of carfilzomib given twice weekly in combination with cyclophosphamide and dexamethasone for patients with newly diagnosed multiple myeloma.
- Trial name
- CHAMPION 2 (NCT01980589)
- Testing
- Carfilzomib, Cyclophosphamide, Dexamethasone
- Where
- 9 sites in United States
- Volunteers
- 22 people
- Sponsor
- Amgen
Multiple Myeloma, Solid Tumors
A Study of Extended Carfilzomib Therapy for Patients Previously Enrolled in Carfilzomib Treatment Protocols
This is a multi-center, open-label, Phase 2 study of carfilzomib to monitor the safety and efficacy of long-term or continuing carfilzomib therapy for patients who previously completed a primary carfilzomib treatment study.
- Trial name
- NCT00884312
- Testing
- Carfilzomib
- Where
- 23 sites in United States, Canada
- Volunteers
- 101 people
- Sponsor
- Amgen
Relapsed Multiple Myeloma, Refractory Multiple Myeloma
Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.
Compare carfizomib, dexamethasone, and daratumumab (KdD) to Carfilzomib and dexamethasone (Kd) in terms of progression free survival (PFS) in participants with multiple myeloma who have relapsed after 1 to 3 prior therapies.
- Trial name
- CANDOR (NCT03158688)
- Testing
- Dexamethasone, Daratumumab, Carfilzomib
- Where
- 113 sites in United States, Australia and 17 more
- Volunteers
- 466 people
- Sponsor
- Amgen
Multiple Myeloma
Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma
Double-blind study will compare the efficacy and assess safety of selinexor plus carfilzomib (Kyprolis®) plus low-dose dexamethasone versus placebo plus carfilzomib plus low-dose dexamethasone in patients with relapsed/refractory…
- Trial name
- SCORE (NCT02628704)
- Testing
- Selinexor, carfilzomib, Dexamethasone
- Where
- 2 sites in United States
- Sponsor
- Karyopharm Therapeutics Inc
Relapsed/Refractory Multiple Myeloma
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
The purpose of this study is to assess the safety, tolerability, and efficacy of sonrotoclax as monotherapy and in various combinations in patients with relapsed/refractory (R/R) multiple myeloma (MM) and chromosomal…
- Trial name
- NCT04973605
- Testing
- Sonrotoclax, Dexamethasone, Carfilzomib
- Where
- 74 sites in United States, Australia and 11 more
- Volunteers
- 246 people
- Sponsor
- BeOne Medicines